Update on the OIG’s Investigations Involving Clinical Research

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

2.2. Challenges and Limitations to Oversight Andres Soosaar, Estonia.
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Tips to a Successful Monitoring Visit
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Identifiability: A Useful or Decrepit Concept in Research Ethics? Sara C. Hull, PhD Faculty, Clinical Center Department of Bioethics Director, NHGRI Bioethics.
The Institutional Review Board. What is an IRB? An IRB is committee set up by an institution to review, approve, and regulate research conducted under.
MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
John Naim, PhD Director Clinical Trials Research Unit
Research Methods for the Social Sciences: Ethics Ryan J. Martin, Ph.D. Thomas N. Cummings Research Fellow March 9, 2010.
Who’s the Boss? Faculty Advisor or Principal Investigator Supervision versus Student Investigator or Study Coordinator Responsibilities Gwenn Snow, MS,
HSP progress in Taiwan 2009 Benjamin I. Kuo, MD, DrPH, CIP Secretariat, Joint Institutional Review Board.
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
WATER, WATER EVERYWHERE? The Water Resources Management Committee of the American Public Works Association.
Federal Aviation Administration Presented to: By: Date: Oversight Throughout the Supply Chain: Is It Adequate? DOT OIG Audit: Assessment of FAA's Risk-Based.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Belinda Seto, Ph.D. Acting Deputy Director for Extramural Research National Institutes of Health Human Subjects Research Enhancements Awards Renaissance.
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Conflict of Interest in Human Subjects Research Bette-Jane Crigger, PhD.
Institutional Review Board Issues for Classroom Research Sharon McWhorter IRB Administrator, The University of Akron (With assistance from Phil Allen,
OBSERVED IN ORO REVIEWS COMPLIANCE ISSUES: OBSERVED IN ORO REVIEWS David A. Weber, Ph.D., FACNP Acting Chief Officer Office of Research.
Agenda for Session Compliance in Clinical Research
Yadvindera (Bobby) Bains MD Director of Radiation Oncology, Laredo Medical Center Adjunct Associate Professor, Dept of Radiation Oncology, University of.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Challenges of 21st Century Clinical Research from an Independent IRB’s View Chesapeake Research Review, Inc. Paul Goebel, CIP Vice President Matthew Whalen,
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
International Research: Pragmatic and Idealistic Thoughts on Capacity Building and the Protection of Human Subjects Jessica Justman, M.D. Institutional.
Office of Human Research Protection Georgia Health Sciences University.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
AIRCRAFT ACCIDENT INVESTIGATION MOOC THE INVESTIGATIVE PROCESS ACCIDENT REPORTS.
ASENT/ISCTM, Feb 23 rd, 2012, Washington DC, USA Pharmaceuticals & Medical Devices Agency Pediatric Drug Development for Neuro-Psychiatric Diseases Yoshiaki.
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
Christine Yalda, J.D., Ph.D. Chair, Human Research Review Committee Grand Valley State University.
Responsibilities of Sponsor, Investigator and Monitor
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
The Role of the HHS Office of Inspector General Summit on Disclosure, Transparency, and Aggregate Spend March 5, 2009 Mary E. Riordan, Office of Counsel.
Subtitle Statement of Capabilities.
Responsibilities of Sponsor, Investigator and Monitor
Patricia M. Alt, Ph.D. Dept. of Health Science Towson University
Introduction to Research: How to develop a scholarly capstone project
What is a Data and Safety Monitoring Plan and how do I get one?
NIH Clinical Trial Requirements
The Institutional Review Board: Who, What, When, Where, Why, and How
Adverse Event Reporting: Trials and Tribulations
Effective Board Governance
Bozeman Health Clinical Research
AAHRPP Accreditation Welcome to the University of Georgia’s presentation for accreditation of the human research protection program (HRPP). This presentation.
IA Reform Progress… Where we now?
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
NOAA-NOS International Programs Office
Clinical Program Manager
Streamlining IRB Procedures for Expanded Access
NATSPEC Governor Seminars 2009
Pharmaceutical Congress: Responding to the Guidance
WATER, WATER EVERYWHERE?
11 iii. Define management and supervision roles and responsibilities
Research, Experimentation, & Clinical Trials
Perfect MatchSM Physician Locator
Research with Human Subjects
Presentation transcript:

Update on the OIG’s Investigations Involving Clinical Research Or, What is the OIG Worrying About Now and Why? Medical Research Summit 2002 Washington, DC Mark R. Yessian, PhD Regional Inspector General Office of Inspector General U.S. Dept. of Health and Human Services

Question #1: What is the OIG’s Role? Independent oversight Assess effectiveness and efficiency

Question #2: What is the OIG’s Track Record in this Field? An extensive review of IRBS and human subject protections Issuance of 10 reports (www.oig.hhs.gov) Testimony at 3 Congressional hearings Site visits to 25-30 IRBs Presentations at 40-50 professional meetings

Question #3: Why has the OIG Become so Interested in Human Subject Protections? 1995 study on investigational devices raised questions about the continuing review role of IRBs Led to broadly based inquiry of challenges facing IRBs June 1998 issuance of high-profile reports on IRBs

June 1998 Report IRBS: A Time for Reform IRBs review too much, too quickly, with little expertise They conduct minimal review of approved research They face conflicts that threaten their independence They provide little training for investigators and board members Neither IRBs nor HHS devote much attention to evaluating the effectiveness of IRBs

Reactions to the Report Raised much concern in the professional community Helped spark some reform

Subsequent OIG Reports Recruiting Human Subjects Globalization of Clinical Trials Clinical Trial Web Sites (To be released this spring)

With Respect to Human Subject Protections, What is the OIG Worrying About Now and Why? Sustaining a capacity for independent review Strengthening continuing review

Sustaining a Capacity for Independent Review Enduring pressures on IRBs Continuing resource constraints Evolving emphasis on responsibility of investigators

Sustaining a Capacity for Independent Review (cont.) Maintaining sufficient expertise Limited organizational independence Minimal outside representation

Strengthening Continuing Review Looking to informed consent as a process, not just a form Examining how the recruitment process really works

Strengthening Continuing Review (cont.) Ensuring the continued safety of subjects making sense of adverse event reports determining the role of data safety monitoring boards

From “Trust” to “Trust but verify”